Evidence map›Paper›PMID 32734509›Full record

ReviewCurrent treatment options in oncology2020

Tumor Treating Fields in the Management of Patients with Malignant Gliomas.

Ashley P Ghiaseddin, David Shin, Kaitlyn Melnick, David D Tran

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current treatment options in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 2 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 2 syntheses or guidelines pooled it, 101 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ashley P GhiaseddinLillian S. Wells Department of Neurosurgery, University of Florida College of Medicine, 1505 SW Archer Road, Gainesville, FL, 32608, USA. ashley.ghiaseddin@neurosurgery.ufl.edu.ORCID 0000-0001-5599-4610
David ShinLillian S. Wells Department of Neurosurgery, University of Florida College of Medicine, 1505 SW Archer Road, Gainesville, FL, 32608, USA.
Kaitlyn MelnickLillian S. Wells Department of Neurosurgery, University of Florida College of Medicine, 1505 SW Archer Road, Gainesville, FL, 32608, USA.
David D TranLillian S. Wells Department of Neurosurgery, University of Florida College of Medicine, 1505 SW Archer Road, Gainesville, FL, 32608, USA. david.tran@neurosurgery.ufl.edu.
University of Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementMalignant gliomas remain a challenging cancer to treat due to limitations in both therapeutic and efficacious options. Tumor treating fields (TTFields) have emerged as a novel, locoregional, antineoplastic treatment modality with favorable efficacy and safety being demonstrated in the most aggressive type of malignant gliomas, glioblastoma (GBM). In 2 large randomized, controlled phase 3 trials, the addition of TTFields was associated with increased overall survival when combined with adjuvant temozolomide (TMZ) chemotherapy in patients with newly diagnosed GBM (ndGBM) and comparable overall survival compared with standard chemotherapy in patients with recurrent GBM (rGBM). TTFields target cancer cells by several mechanisms of action (MoA) including suppression of proliferation, migration and invasion, disruption of DNA repair and angiogenesis, antimitotic effects, and induction of apoptosis and immunogenic cell death. Having several MoAs makes TTFields an attractive modality to combine with standard, salvage, and novel treatment regimens (e.g., radiotherapy, chemotherapy, and immunotherapy). Treatment within the field of malignant gliomas is evolving to emphasize combinatorial approaches that work synergistically to improve patient outcomes. Here, we review the current use of TTFields in GBM, discuss MOA and treatment delivery, and consider the potential for its wider adoption in other gliomas.

Indexed as

AlgorithmsBrain NeoplasmsClinical Decision-MakingClinical Trials as TopicCombined Modality TherapyDisease ManagementFactor Analysis, StatisticalGlioblastomaGliomaHumansRadiofrequency AblationTreatment OutcomeAlternating electric fieldsCNS tumorsGlioblastomaMalignant gliomaOptune®Tumor treating fields

Identifiers

PMID32734509
PMCPMC7391234
OpenAlexW3045948442

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.